Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 14, 2014

View Archived Issues

Academic team divulges novel FimH inhibitors

VolitionRx enters into agreement with University of Oxford for endometriosis diagnostic

Radboud University Medical Center wins NuGEN award for sarcoma genomics research

Medgenics and CHOP collaborate on pediatric rare and orphan genetic diseases

Enterome and AbbVie establish microbiome collaboration in Crohn's disease

Glionova Therapeutics raises financing for clinical development of glioblastoma candidate

BioCardia to conduct phase III trial of autologous bone marrow cell therapy for heart failure

GenomeDx and Mayo Clinic collaborate on expanded use of prostate cancer test

FDA approves supplemental NDAs for Invega Sustenna

First-in-human results for GSK-2878175 in healthy volunteers and patients with HCV

Advaxis submits IND for phase I/II study of ADXS-HPV and MEDI-4736 for HPV-related cancers

Phase II study of masitinib in hepatocellular cancer recommended to continue by DSMB

Safety and pharmacokinetic results for first-in-class HBV core inhibitor NVR-3-778

Suppression of Bcl-xL in hepatocellular carcinoma cells by TPU-0014

Presage expands cancer research agreement with Takeda

Arrien Pharmaceuticals patent details novel dual ITK/JAK3 inhibitors

Innocrin Pharmaceuticals to participate in phase II trial of VT-464 in prostate cancer

New lead candidates for broad-spectrum antimalarial drugs presented

University of Queensland developing new vaccine technology for polio

Japanese researchers describes anti-NLRR-1 MAbs

Merck & Co. presents preliminary phase I results for recombinant dengue vaccine

Janssen licenses Geron's imetelstat

Quatsomes EGF formulation developed to treat diabetic foot ulcers

Clinical trials of favipiravir and brincidofovir planned in Ebola virus outbreak region

Mitsubishi Tanabe seeks Japanese approval of Radicut for ALS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...